Olafertinib
Olafertinib (CK-101) is an orally available, third generation and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) . Olafertinib selectively inhibits both EGFR-TKI-sensitizing and resistance mutations with minimal activity on wild-type EGFR. Olafertinib can be used in research for non-small cell lung cancer (NSCLC) with EGFR mutations and other advanced malignancies[1][2].
Product Specifications
CAS Number
1660963-42-7
Product Name Alternative
CK-101; RX518
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/EGFR-IN-3.html
Purity
99.51
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
OCCN1CCN(C2=C(F)C(F)=C(NC3=NC=C4C(C(C5=CC(NC(C=C)=O)=CC=C5)=CC=C4)=N3)C=C2)CC1
Molecular Formula
C29H28F2N6O2
Molecular Weight
530.57
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MUC18 / Mucin 18 / CD146 (OJ79c), CF740 conjugate, 0.1mg/mL
CD44 Standard (156-3C11), CF594 conjugate, 0.1mg/mL
CD54 / ICAM-1 (15.2), CF740 conjugate, 0.1mg/mL
Ep-CAM / CD326 (VU-1D9), CF555 conjugate, 0.1mg/mL
Vimentin (VM1170), CF647 conjugate, 0.1mg/mL
